Europe moves closer to new hemophilia A treatment approval

In September 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting marketing authorization for Novo Nordisk's Frehemgo (denecimig) for routine prophylaxis of bleeding episodes in hemophilia A patients. The treatment, which can be administered subcutaneously up to once monthly, offers a more flexible option. The recommendation is based on the phase 3 FRONTIER2 trial, and the European Commission is expected to make a final decision within two months.

Frehemgo EMA approval recommendation

• ▪The European Medicines Agency's Committee for Medicinal Products for Human Use recommended Frehemgo (denecimig) for routine prophylaxis of bleeding episodes in hemophilia A patients with factor VIII inhibitors.
• ▪At its September 2026 meeting, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting marketing authorization for Frehemgo (denecimig) by Novo Nordisk.

Hemophilia A disease background

• ▪Hemophilia A is an inherited bleeding disorder caused by insufficient or absent clotting factor VIII, leading to spontaneous and injury-related bleeding into joints, muscles, and soft tissues.
• ▪Some hemophilia A patients develop inhibitors against replacement factor VIII, which makes conventional factor concentrates ineffective and complicates long-term management.

Denecimig mechanism of action

• ▪In the phase 3 FRONTIER2 trial, weekly and monthly prophylaxis with denecimig reduced annualized treated bleeding rates in patients aged 12 years or older with hemophilia A, with or without factor VIII inhibitors.
• ▪Frehemgo (denecimig) is designed to substitute for the missing cofactor function of factor VIIIa, helping restore the body's thrombin-generation capacity and support clot formation independent of native factor VIII.
• ▪Frehemgo (denecimig) is designed to be administered via a single-use prefilled pen on a once-weekly, once-every-2-weeks, or once-monthly schedule.

FRONTIER2 trial clinical evidence

• ▪According to the European Medicines Agency's Committee for Medicinal Products for Human Use, the most common side effects of Frehemgo (denecimig) are injection-site reactions, increased prothrombin fragment 1.2, and increased fibrin D-dimer.
• ▪The European Medicines Agency's Committee for Medicinal Products for Human Use's positive opinion on Frehemgo (denecimig) will be sent to the European Commission for a legally binding decision on European Union-wide marketing authorization.